How Is AstraZeneca Plc (LSE:AZN) Trading Today?

AstraZeneca Plc (LSE:AZN) shares edged higher by 0.06% to around 13,938.0p today. The move follows third-quarter results showing total Revenue growth of 7% and the reconfirmation of full-year guidance.

For the nine months to 30 September 2026, total revenue was $46.9 billion, up 7% at constant exchange rates, and Core EPS rose 14% to $8.00. Third-quarter revenue was $16.2 billion, with Core EPS up 19%.

The update showed continued progress across the company's therapy areas and a busy pipeline, with 12 positive Phase III programme readouts in the year to date.

About AstraZeneca Plc

AstraZeneca is a global, science-led biopharmaceutical company focused on the discovery, development and commercialisation of prescription medicines. Its main therapy areas are Oncology, Cardiovascular, Renal and Metabolism, Respiratory and Immunology, and Rare Disease, with a growing presence in vaccines and immune therapies.

The company operates in more than 100 countries and has a pipeline of around 180 projects, of which 116 are new molecular entities or major life-cycle management projects in Phase II or Phase III.

LSE:AZN is a significant FTSE 100 healthcare constituent and one of the largest listed pharmaceutical groups in Europe.

Investment in R&D is a central feature of the pharmaceutical model, and AstraZeneca invests a significant share of revenue in its pipeline. Success depends on the combination of scientific discovery, clinical execution and the ability to bring medicines to patients across a wide range of healthcare systems.

9M and Q3 2026 Financial Performance

Core operating profit increased 14% to $16.4 billion for the nine months, and the gross Margin was 82%. Reported EPS rose 11% to $5.62 for the period and 26% to $2.02 for the third quarter.

Core R&D represented 22% of total revenue in the quarter, reflecting Investment in an increasing number of trials, new technologies and projects added through Business development. Core SG&A was 24% of revenue, supporting current and future launches.

Therapy Area Highlights

Oncology was the largest therapy area at $21.9 billion, up 16% and representing 47% of revenue. Rare Disease revenue grew 11% to $7.5 billion, and Respiratory and Immunology grew 10% to $7.3 billion.

Alliance revenue, which reflects AstraZeneca's share of profits on medicines sold with partners such as Enhertu and Tezspire, rose 36% in the quarter to $1,107 million. Double-digit growth in these areas offset the impact of generic competition for Farxiga and Brilinta and volume-based procurement in China.

Pipeline Progress

Since the previous results announcement, AstraZeneca has secured 47 approvals in major regions, including first approvals for four new medicines: Etcamah, Baxfendy, Klygefa and Amlypave. First Phase III data were also reported for three new molecular entities: tozorakimab, efzimfotase alfa and sonesitatug vedotin.

The company has delivered 14 new molecular entities against a target of 20 by 2030. Management said the 12 positive Phase III readouts have a collective peak-year revenue potential well in excess of ten billion dollars, and that 2027 readouts could represent more than twenty billion dollars.

The company has also highlighted the potential of technologies including antibody-drug conjugates, bispecific antibodies and radioconjugates. These platforms are intended to broaden the range of conditions that can be treated and to extend the life of established franchises through new indications and combinations.

Guidance Reconfirmed

AstraZeneca reconfirmed its 2026 guidance of mid-to-high single-digit percentage growth in total revenue and low double-digit percentage growth in Core EPS at constant exchange rates, with a Core tax rate of 18% to 22%.

If exchange rates for the remainder of the year remain at September levels, total revenue is expected to benefit from a low single-digit percentage positive currency effect.

Growth Catalysts

Late-stage pipeline delivery, new launches, expanding oncology indications and rare disease growth are the main themes for LSE:AZN. Chief Executive Pascal Soriot said the company has multiple potential blockbuster Assets in late-stage development and is on track to deliver its 2030 ambition.

Technologies such as antibody-drug conjugates and next-generation respiratory treatments are also scaling, adding to the breadth of the portfolio.

Factors to Monitor

Pharmaceutical performance depends on clinical trial outcomes, regulatory timelines, pricing environments and Patent expiries. Trial results are never certain, and the timing of approvals can influence revenue phasing.

Investors typically follow quarterly sales, pipeline updates and upcoming Phase III readouts.

Conclusion

AstraZeneca's 0.06% gain to around 13,938.0p today follows nine-month revenue of $46.9 billion, Core EPS of $8.00 and reconfirmed guidance.

Oncology growth, rare disease, pipeline delivery and approvals remain the central themes for LSE:AZN.